Royal Bank of Canada’s Vertex Pharmaceuticals VRTX Stock Holding History

Royal Bank of Canada’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100,000	Closed	-$45.3M	–	7739
2025 Q4	$45.3M	Buy	+100,000	New	+$43.1M	0.01%	995
2020 Q1	–	Sell	-170,000	Closed	-$37.2M	–	7063
2019 Q4	$37.2M	Buy	+170,000	New	+$34.4M	0.01%	766
2019 Q3	–	Sell	-257,900	Closed	-$47.3M	–	7161
2019 Q2	$47.3M	Buy	+257,900	New	+$45.1M	0.02%	612
2018 Q4	–	Sell	-200,400	Closed	-$38.6M	–	7146
2018 Q3	$38.6M	Buy	+200,400	New	+$35.7M	0.02%	712
2015 Q3	–	Sell	-20,000	Closed	-$2.47M	–	6801
2015 Q2	$2.47M	Buy	+20,000	New	+$2.52M	﹤0.01%	2155
2013 Q3	–	Sell	-10,000	Closed	-$799K	–	6275
2013 Q2	$799K	Buy	+10,000	New	+$736K	﹤0.01%	2758

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Royal Bank of Canada's VRTX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Vertex Pharmaceuticals (VRTX) stake by 6.9% in Q1 2026, selling an estimated $38.5M and leaving 1,111,871 shares worth $496M. The position accounts for 0.09% of the portfolio, ranked #218.

Royal Bank of Canada first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $788M in Q2 2024. 1,692 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Royal Bank of Canada held 1,111,871 shares of Vertex Pharmaceuticals worth $496M as of Q1 2026.
Royal Bank of Canada sold 82,641 Vertex Pharmaceuticals shares in Q1 2026, an estimated $38.5M.
Vertex Pharmaceuticals made up 0.09% of Royal Bank of Canada's portfolio in Q1 2026, its #218 holding.
Royal Bank of Canada first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Royal Bank of Canada's Vertex Pharmaceuticals position peaked at $788M in Q2 2024.
1,692 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.